Eli Lilly: Investment Portfolio & Startup News
Eli Lilly
To add a bio or update investment portfolio click update information.
Investment Portfolio


T-Therapeutics closes a £100m Series B led by Advent Life Sciences and British Business Bank to take its cancer and autoimmune treatments into clinical trials
T-Therapeutics is a biotechnology company developing T cell engager treatments based on human T cell receptors. Its drug programmes target cancer and autoimmune diseases.


Alchemab Therapeutics raises £24m Series A extension led by Ono Venture Investment to advance AI-enabled antibody platform
Alchemab identifies naturally occurring protective antibodies using AI and patient data, developing new therapies based on disease resilience rather than traditional target discovery.


Laverock Therapeutics raises over £20m in expanded seed round led by Calculus Capital to advance gene control therapies
Laverock Therapeutics is developing programmable gene control technologies that enable advanced therapies to respond dynamically to disease, improving precision, safety and effectiveness in cell-based treatments.


Maxion Therapeutics raises £58m in Series A led by General Catalyst to advance KnotBody pipeline
Maxion Therapeutics develops antibody-based KnotBody drugs targeting ion channels and GPCRs, advancing new treatments for inflammatory, pain and cardiovascular diseases with improved selectivity.
- 1(12 months)
- lilly.com/uk
More venture news
- 17 Nov 2026

Model MLModel ML secures a £190m Series B led by General Atlantic and QED Investors to expand its AI operating system for financial services
Series BFintech - 16 Nov 2026

SubdialSubdial secures a £15m Series B led by Gresham House Ventures to buy and sell pre-owned watches
Series BConsumer - 12 Nov 2026

GriffinGriffin closes a £15m Series B led by Octagon Partners to add cards and stablecoin payments to its banking platform
Series BFintech